Utilize este identificador para referenciar este registo: http://hdl.handle.net/10400.14/4437
Título: Recombinant human erythropoietin treatment protects the cardio-renal axis in a model of moderate chronic renal failure
Autor: Teixeira, Ana Margarida
Garrido, Patrícia
Santos, Paulo
Alves, Rui
Parada, Belmiro
Costa, Elísio
Almeida, Anabela
Teixeira-Lemos, Edite
Sereno, José
Pinto, Rui
Belo, Luís
Santos-Silva, Alice
Teixeira, Frederico
Reis, Flávio
Palavras-chave: Moderate chronic renal failure
rhEPO treatment
Cardio-renal protection
Proliferation
Hypertroph
Apoptosis
Data: 2010
Editora: Informa Healthcare
Citação: TEIXEIRA, Ana Margarida ... [et al.] - Recombinant human erythropoietin treatment protects the cardio-renal axis in a model of moderate chronic renal failure. Renal Failure. ISSN 0886-022X .Vol. 32, n.º 9 (2010), p. 1073-1080
Resumo: Chronic kidney disease (CKD) patients develop anemia because of the low kidney erythropoietin (EPO) production, thus promoting cardiovascular complications. The degree of renal insufficiency might determine the moment to start recombinant human erythropoietin (rhEPO) therapy, but the molecular basis for these options deserves better elucidation. This study aimed to clarify the cardio-renal effects of earlier rhEPO ther- 20 apy in rats with moderate chronic renal failure (CRF). Four groups of rats were evaluated for 15 weeks (control; rhEPO - 50 Ill/kg/week; CRF - 3/4 nephrectomy; CRF + rhEPO) to assess renal and hematology data, EPO levels, blood pressure, heart rate, peripheral catecholamines contents, serum-transforming growth factor-31 (TGF-f11), kidney gene expression of EPO, Caspase 9 (Casp9), and vascular endothelial growth factor (Vegf). This model of moderate CRF showed moderate and corrected anemia, hypertension, tachycardia, sympa- 25 thetic overactivity, and increased serum TGF-31 content. The remnant kidney showed a proliferative profile, with hypertrophy, downregulated gene expression of EPO, and upregulated gene expression of Vegf and Casp9. rhEPO treatment promoted erythrocytosis and prevented tachycardia and catecholamines increment, with a rise of serum TGF-$1. Furthermore, the decreased kidney gene expression of EPO and the overexpression of Casp9 were prevented, demonstrating a renoprotective action on the remnant kidney. In conclusion, 30 rhEPO therapy promotes a protective effect on the cardio-renal axis, which might be mainly attributed to its pro-proliferative and anti-apoptotic properties. These findings might recommend its use in earlier stages of CRF, acting as an erythropoiesis stimulating agent, to efficiently correct not only the anemia, one of the major complications in these patients, but also the succeeding adverse cardio-renal effects.
Peer review: yes
URI: http://hdl.handle.net/10400.14/4437
Versão do Editor: http://informahealthcare.com/doi/abs/10.3109/0886022X.2010.509897?journalCode=rnf
Aparece nas colecções:ICS(P) - Artigos em revistas internacionais com Arbitragem / Papers in international journals with Peer-review

Ficheiros deste registo:
Ficheiro Descrição TamanhoFormato 
2010_ICS_Costa_Elisio-dig.PDF406,47 kBAdobe PDFVer/Abrir    Acesso Restrito. Solicitar cópia ao autor!


FacebookTwitterDeliciousLinkedInDiggGoogle BookmarksMySpace
Formato BibTex MendeleyEndnote Degois 

Todos os registos no repositório estão protegidos por leis de copyright, com todos os direitos reservados.